Differential effects of selective COX-2 inhibitors on cell cyde regulation and proliferation of glioblastoma cell lines

Adel Kardosh, Martina Blumenthal, Wei Jun Wang, Thomas C. Chen, Axel H. Schönthal

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

It is well established that traditional NSAIDs, which inhibit cyclooxygenase (COX) 1 and COX-2, have the potential to reduce the risk of colorectel cancer. New generation COX inhibitors have been developed that selectively inhibit COX-2, which might cause less side effects while still retaining their therapeutic potential. As patients with brain tumors, such as glioblastoma, exhibit a very poor prognosis, we began to explore whether COX inhibitors could be useful for the treatment of this type of tumor. We found that celecoxib inhibited the proliferation of various glioblastoma cell lines in vitro much more potently than traditional NSAIDs. In addition, although several different selective COX-2 inhibitors potently reduced PGES levels in these cells, none of them exerted anti-proliferative effects that were comparable to celecoxib. The addition of external PGE2 to celecoxib-treated cells did not restore proliferation, indicating that growth inhibition by celecoxib was not mediated via the blockage of PGE2 production. In an effort to determine the underlying molecular processes that might mediate celecoxib's potent anti-proliferative effects, we found a loss of the activity of cyclin-dependent kinases, the essential regulators of cell proliferation, which was due to the transcriptional downregulation of cyclin A and cyclin B expression. Taken together, our results show that celecoxib exerts COX-2-independent anti-proliferative effects on glioblastoma cell growth, which are more potent than those of other selective COX-2 inhibitors or traditional NSAIDs, and which are mediated via the transcriptional inhibition of two essential components of the cell cycle machinery, cyclin A and cyclin B.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalCancer Biology and Therapy
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Celecoxib
Cyclooxygenase 2 Inhibitors
Glioblastoma
Cell Line
Non-Steroidal Anti-Inflammatory Agents
Cyclooxygenase 2
Cyclin B
Cyclin A
Cyclooxygenase Inhibitors
Dinoprostone
Cyclooxygenase 1
Cyclin-Dependent Kinases
Growth
Brain Neoplasms
Neoplasms
Cell Cycle
Down-Regulation
Cell Proliferation

Keywords

  • Bextra
  • CDK
  • Celebrex
  • Celecoxib
  • Cell cycle
  • Cyclin
  • Flurbiprofen
  • Indomethacin
  • Ketoprofen
  • NS-398
  • NSAIDs
  • Piroxicam
  • Rofecoxib
  • Sulindac
  • Valdecoxib
  • Vioxx

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Differential effects of selective COX-2 inhibitors on cell cyde regulation and proliferation of glioblastoma cell lines. / Kardosh, Adel; Blumenthal, Martina; Wang, Wei Jun; Chen, Thomas C.; Schönthal, Axel H.

In: Cancer Biology and Therapy, Vol. 3, No. 1, 01.01.2004, p. 55-62.

Research output: Contribution to journalArticle

Kardosh, Adel ; Blumenthal, Martina ; Wang, Wei Jun ; Chen, Thomas C. ; Schönthal, Axel H. / Differential effects of selective COX-2 inhibitors on cell cyde regulation and proliferation of glioblastoma cell lines. In: Cancer Biology and Therapy. 2004 ; Vol. 3, No. 1. pp. 55-62.
@article{79c6f8594d144feebe550a72705b85f9,
title = "Differential effects of selective COX-2 inhibitors on cell cyde regulation and proliferation of glioblastoma cell lines",
abstract = "It is well established that traditional NSAIDs, which inhibit cyclooxygenase (COX) 1 and COX-2, have the potential to reduce the risk of colorectel cancer. New generation COX inhibitors have been developed that selectively inhibit COX-2, which might cause less side effects while still retaining their therapeutic potential. As patients with brain tumors, such as glioblastoma, exhibit a very poor prognosis, we began to explore whether COX inhibitors could be useful for the treatment of this type of tumor. We found that celecoxib inhibited the proliferation of various glioblastoma cell lines in vitro much more potently than traditional NSAIDs. In addition, although several different selective COX-2 inhibitors potently reduced PGES levels in these cells, none of them exerted anti-proliferative effects that were comparable to celecoxib. The addition of external PGE2 to celecoxib-treated cells did not restore proliferation, indicating that growth inhibition by celecoxib was not mediated via the blockage of PGE2 production. In an effort to determine the underlying molecular processes that might mediate celecoxib's potent anti-proliferative effects, we found a loss of the activity of cyclin-dependent kinases, the essential regulators of cell proliferation, which was due to the transcriptional downregulation of cyclin A and cyclin B expression. Taken together, our results show that celecoxib exerts COX-2-independent anti-proliferative effects on glioblastoma cell growth, which are more potent than those of other selective COX-2 inhibitors or traditional NSAIDs, and which are mediated via the transcriptional inhibition of two essential components of the cell cycle machinery, cyclin A and cyclin B.",
keywords = "Bextra, CDK, Celebrex, Celecoxib, Cell cycle, Cyclin, Flurbiprofen, Indomethacin, Ketoprofen, NS-398, NSAIDs, Piroxicam, Rofecoxib, Sulindac, Valdecoxib, Vioxx",
author = "Adel Kardosh and Martina Blumenthal and Wang, {Wei Jun} and Chen, {Thomas C.} and Sch{\"o}nthal, {Axel H.}",
year = "2004",
month = "1",
day = "1",
doi = "10.4161/cbt.3.1.571",
language = "English (US)",
volume = "3",
pages = "55--62",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Differential effects of selective COX-2 inhibitors on cell cyde regulation and proliferation of glioblastoma cell lines

AU - Kardosh, Adel

AU - Blumenthal, Martina

AU - Wang, Wei Jun

AU - Chen, Thomas C.

AU - Schönthal, Axel H.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - It is well established that traditional NSAIDs, which inhibit cyclooxygenase (COX) 1 and COX-2, have the potential to reduce the risk of colorectel cancer. New generation COX inhibitors have been developed that selectively inhibit COX-2, which might cause less side effects while still retaining their therapeutic potential. As patients with brain tumors, such as glioblastoma, exhibit a very poor prognosis, we began to explore whether COX inhibitors could be useful for the treatment of this type of tumor. We found that celecoxib inhibited the proliferation of various glioblastoma cell lines in vitro much more potently than traditional NSAIDs. In addition, although several different selective COX-2 inhibitors potently reduced PGES levels in these cells, none of them exerted anti-proliferative effects that were comparable to celecoxib. The addition of external PGE2 to celecoxib-treated cells did not restore proliferation, indicating that growth inhibition by celecoxib was not mediated via the blockage of PGE2 production. In an effort to determine the underlying molecular processes that might mediate celecoxib's potent anti-proliferative effects, we found a loss of the activity of cyclin-dependent kinases, the essential regulators of cell proliferation, which was due to the transcriptional downregulation of cyclin A and cyclin B expression. Taken together, our results show that celecoxib exerts COX-2-independent anti-proliferative effects on glioblastoma cell growth, which are more potent than those of other selective COX-2 inhibitors or traditional NSAIDs, and which are mediated via the transcriptional inhibition of two essential components of the cell cycle machinery, cyclin A and cyclin B.

AB - It is well established that traditional NSAIDs, which inhibit cyclooxygenase (COX) 1 and COX-2, have the potential to reduce the risk of colorectel cancer. New generation COX inhibitors have been developed that selectively inhibit COX-2, which might cause less side effects while still retaining their therapeutic potential. As patients with brain tumors, such as glioblastoma, exhibit a very poor prognosis, we began to explore whether COX inhibitors could be useful for the treatment of this type of tumor. We found that celecoxib inhibited the proliferation of various glioblastoma cell lines in vitro much more potently than traditional NSAIDs. In addition, although several different selective COX-2 inhibitors potently reduced PGES levels in these cells, none of them exerted anti-proliferative effects that were comparable to celecoxib. The addition of external PGE2 to celecoxib-treated cells did not restore proliferation, indicating that growth inhibition by celecoxib was not mediated via the blockage of PGE2 production. In an effort to determine the underlying molecular processes that might mediate celecoxib's potent anti-proliferative effects, we found a loss of the activity of cyclin-dependent kinases, the essential regulators of cell proliferation, which was due to the transcriptional downregulation of cyclin A and cyclin B expression. Taken together, our results show that celecoxib exerts COX-2-independent anti-proliferative effects on glioblastoma cell growth, which are more potent than those of other selective COX-2 inhibitors or traditional NSAIDs, and which are mediated via the transcriptional inhibition of two essential components of the cell cycle machinery, cyclin A and cyclin B.

KW - Bextra

KW - CDK

KW - Celebrex

KW - Celecoxib

KW - Cell cycle

KW - Cyclin

KW - Flurbiprofen

KW - Indomethacin

KW - Ketoprofen

KW - NS-398

KW - NSAIDs

KW - Piroxicam

KW - Rofecoxib

KW - Sulindac

KW - Valdecoxib

KW - Vioxx

UR - http://www.scopus.com/inward/record.url?scp=3142596577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142596577&partnerID=8YFLogxK

U2 - 10.4161/cbt.3.1.571

DO - 10.4161/cbt.3.1.571

M3 - Article

VL - 3

SP - 55

EP - 62

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 1

ER -